ASSESSING CLINICAL EFFICACY AND TRIAL DESIGN PARAMETERS FOR TREATMENTS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A NOVEL QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL.

被引：0
|
作者：
Rieger, T. R. [1 ]
Allen, R. J. [1 ]
Musante, C. J. [1 ]
机构：
[1] Pfizer Inc, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
QSP-014
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease
    Zhang, Zhongyong
    Qi, Yueying
    Kong, Wubao
    Jin, Qianqian
    Wang, Xiaoyun
    Dong, Yanfang
    Wang, Yuansong
    Li, Huajun
    MEDICAL SCIENCE MONITOR, 2018, 24 : 7399 - 7404
  • [42] Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial
    Zelber-Sagi, Shira
    Buch, Assaf
    Yeshua, Hanny
    Vaisman, Nahum
    Webb, Muriel
    Harari, Gil
    Kis, Ofer
    Fliss-Isakov, Naomi
    Izkhakov, Elena
    Halpern, Zamir
    Santo, Erwin
    Oren, Ran
    Shibolet, Oren
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4382 - 4392
  • [43] Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial
    Rafie, Roya
    Hosseini, Seyed Ahmad
    Hajiani, Eskandar
    Malehi, Amal Saki
    Mard, Seyed Ali
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2020, 13 : 35 - 45
  • [44] Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial
    Shira Zelber-Sagi
    Assaf Buch
    Hanny Yeshua
    Nahum Vaisman
    Muriel Webb
    Gil Harari
    Ofer Kis
    Naomi Fliss-Isakov
    Elena Izkhakov
    Zamir Halpern
    Erwin Santo
    Ran Oren
    Oren Shibolet
    World Journal of Gastroenterology, 2014, (15) : 4382 - 4392
  • [45] A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices
    Prins, Grietje H.
    Luangmonkong, Theerut
    Oosterhuis, Dorenda
    Mutsaers, Henricus A. M.
    Dekker, Frank J.
    Olinga, Peter
    NUTRIENTS, 2019, 11 (03):
  • [46] Pathophysiologic model of non-alcoholic fatty liver disease using precision-cut liver slices
    Luangmonkong, Theerut
    Weymaere, Jana
    Suriguga, Su
    Oosterhuis, Dorenda
    Schuppan, Detlef
    Mutsaers, Henricus A.
    Olinga, Peter
    HEPATOLOGY, 2016, 64 : 786A - 786A
  • [47] QUANTITATIVE ASSESSMENT OF HISTOPATHOLOGICAL CARDINAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE USING MACHINE LEARNING
    Langford, Caitlin
    Roy, Abhishek
    Goldfinger, Marc
    Olchanyi, Mark
    Bogush, Alexander
    Kazimianec, Arina
    Kendall, Tim
    Fryer, Eve
    Goldin, Robert D.
    Brady, Michael
    Banerjee, Rajarshi
    Fleming, Kenneth A.
    HEPATOLOGY, 2021, 74 : 982A - 982A
  • [48] Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial
    Al-Baiaty, Farah D. R.
    Ishak, Shareena
    Zaki, Faizah Mohd
    Masra, Farin
    Aziz, Dayang Anita Abdul
    Zin, Wan Nurulhuda Wan Md
    Hing, Erica Yee
    Zaman, Azrina Syarizad Kuthubul
    Wahab, Norhazlina Abdul
    Nawawi, Khairul Najmi Muhammad
    Hamid, Zalina
    Ali, Raja Affendi Raja
    Mokhtar, Norfilza Mohd
    BMC PEDIATRICS, 2024, 24 (01)
  • [49] The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial
    Zahra Yari
    Makan Cheraghpour
    Seyed Moayed Alavian
    Mehdi Hedayati
    Hassan Eini-Zinab
    Azita Hekmatdoost
    European Journal of Clinical Nutrition, 2021, 75 : 99 - 111
  • [50] The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial
    Yari, Zahra
    Cheraghpour, Makan
    Alavian, Seyed Moayed
    Hedayati, Mehdi
    Eini-Zinab, Hassan
    Hekmatdoost, Azita
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2021, 75 (01) : 99 - 111
12345